A small phase 1 study is evaluating the safety and tolerability of blinatumomab combined with nivolumab targeting PD-1 and/or ipilimumab targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) in patients with R/R B-ALL [167]. The gene discussed is PDCD1; the disease is acute lymphoblastic leukemia.